Substance / Medication

Ropinirole

Overview

Active Ingredient
ropinirole
RxNorm CUI
72302

Indications

Ropinirole extended-release tablets are indicated for the treatment of Parkinson’s disease.

Labeler: Solco Healthcare US, LLCUpdated: 2025-05-23T00:00:00.000ZFull label on DailyMed

Contraindications

When this intervention should not be used

Ropinirole extended-release tablets are contraindicated in patients known to have a hypersensitivity/allergic reaction (including urticaria, angioedema, rash, pruritus) to ropinirole or any of the excipients.

Indications & Related Conditions

Conditions associated via SNOMED clinical relationships

Administration & Protocol

Dosing, route, and treatment protocol

Detailed dosage and administration information is available in the full FDA drug label.

View full prescribing information on DailyMed

Monitoring & Follow-Up

Biomarkers relevant to this intervention via related conditions

No monitoring biomarkers have been mapped yet. Biomarker-intervention linkages are derived through related conditions and will expand as the knowledge graph grows.

Clinical Trials

6 trials linked to this intervention

6
Total Trials
0
Recruiting
3
With Results

Research Evidence

Published studies and systematic reviews

Sort:
Impulse control disorders in Parkinson's disease patients treated with pramipexole and ropinirole: a systematic review and meta-analysis.
Soileau Lenise G, Talbot Norris C, Storey Nicholas R et al. · Neurol Sci · 2024
PMID: 38079019Meta-Analysis
Prevalence of Nausea and Vomiting in Adults Using Ropinirole: A Systematic Review and Meta-Analysis.
Kurin Michael, Bielefeldt Klaus, Levinthal David J · Dig Dis Sci · 2018
PMID: 29383607Meta-Analysis
Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke C E, Deane K H · Cochrane Database Syst Rev · 2001
PMID: 11279719Meta-Analysis
Ropinirole for levodopa-induced complications in Parkinson's disease.
Clarke C E, Deane K H · Cochrane Database Syst Rev · 2001
PMID: 11279718Meta-Analysis
Ropinirole versus bromocriptine for levodopa-induced complications in Parkinson's disease.
Clarke C E, Deane K H · Cochrane Database Syst Rev · 2000
PMID: 10908504Meta-AnalysisFull text (PMC)
Ropinirole for levodopa-induced complications in Parkinson's disease.
Clarke C E, Deane K H · Cochrane Database Syst Rev · 2000
PMID: 10908503Meta-Analysis
Comparison of pramipexole versus ropinirole in the treatment of Parkinson's disease.
Gencler Onur Serdar, Oztekin Nese, Oztekin Mehmet Fevzi · Ideggyogy Sz · 2022
PMID: 35112520RCT

Research data from MEDLINE/PubMed

Benefits & Expected Outcomes

Benefits, expected outcomes, efficacy data, and NNT (Number Needed to Treat) are pending physician authorship and evidence review.

Risks & Side Effects

Adverse reaction and safety data for this drug is sourced from the FDA-approved label.

View adverse reactions & drug interactions on DailyMed

Related Symptoms

Symptoms associated with conditions this intervention addresses

No related symptoms have been mapped yet. Symptom linkages are derived through associated conditions.

Alternatives & Comparisons

Alternative treatments, comparison data, and clinical decision support are pending physician authorship.

Medical Disclaimer

This information is for educational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult with a qualified healthcare provider regarding any medical condition or treatment plan.

Do not start, stop, or change any treatment without consulting your healthcare provider.

Quick Facts

Type
Substance / Medication
Fully Specified Name
Ropinirole (substance)
SNOMED CT
372499000
UMLS CUI
C0244821
RxNorm CUI
72302
Labeler
Solco Healthcare US, LLC

Clinical Data

This intervention maps to 1 entities in the Ltrl knowledge graph.

1
Conditions
0
Biomarkers
0
Specialists
0
Symptoms
6
Clinical Trials

Data is sourced from SNOMED CT, UMLS, and the Ltrl clinical knowledge graph. Content sections marked as pending require physician authorship. Consult a healthcare provider before starting any treatment.